Ashish Sehgal has joined Sabinsa Europe GmbH as president of Sabinsa Europe, based in the Sabinsa Europe office in Langen, Germany. 

Mr. Sehgal, a pharmaceutical professional with over 20 years of experience in the generic pharmaceutical industry, has worked with large Indian companies such as Ranbaxy, Dabur and Matrix and successfully set up International operations in Africa, South America and Europe for these companies. Mr. Sehgal was posted to Belgium in 2007 as business development head for Docpharma, a company bought by Matrix. After Matrix was acquired by U.S. generic major, Mylan, Ashish continued to be responsible for Business Development and integration operations for the group companies.

Before joining Sabinsa, Mr. Sehgal worked as a pharmaceutical consultant to European and Indian companies under the aegis of his company, VAYA Pharmaceuticals.

Mr. Sehgal is a chemical engineer and MBA by qualification. He has also completed his masters in management degree under the Sloan Masters Programme from London Business School, University of London.

“Mr. Sehgal’s experience with regulatory agencies in Europe will be extremely valuable to Sabinsa, given that the major drug companies are interested in nutraceutical ingredient products,” said Sabinsa’s President of Global Expansion and Operations Mr. Madhu Subramanian. “Ashish’s business development experience in Europe will be invaluable in managing our growth in the areas of nutraceuticals, chemicals and cosmetics, as well.”

“Sabinsa’s innovative products and significant patent portfolio assures them a sound position in the European markets,” said Mr. Sehgal. “I’m pleased to have joined this team and look forward to growing the business.”